This site is intended for health professionals only

Published on 26 April 2007

Share this story:
Twitter
LinkedIn

Miraxion fails to meet endpoints in phase III trials for Huntington’s disease

teaser

US life sciences information service BioSpace reports on the resultsof two phase III trials evaluating Miraxion (semisynthetic ethyl-EPAderivative) in treating Huntington’s disease, which have been releasedby Amarin Corporation. In both double-blind, placebo-controlledstudies, patients with the disease were randomised to receive eitherplacebo or Miraxion (1g bd) for six months. The primary endpoint of thetrials was a change in the Total Motor Score 4 component of the UnifiedHuntington’s Disease Rating Scale; secondary endpoints includedcognition and Total Functional Capacity outcomes. No statisticallysignificant difference was found between the placebo and Miraxiongroups in any of the endpoints studied.

National Electronic Library for Medicines 25/4/2007

 



Most read




Latest Issue

Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine
Share this story:
Twitter
LinkedIn